Suppr超能文献

经阴道超声检查与子宫内膜活检在绝经后激素替代治疗使用者子宫内膜监测中的比较。

Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users.

作者信息

Hänggi W, Bersinger N, Altermatt H J, Birkhäuser M H

机构信息

Department of Obstetrics and Gynaecology, University Hospital, University of Bern, Switzerland.

出版信息

Maturitas. 1997 Jun;27(2):133-43. doi: 10.1016/s0378-5122(97)00037-6.

Abstract

OBJECTIVES

To compare transvaginal ultrasonography with histological findings in endometrial evaluation of postmenopausal women using hormone replacement therapy and to evaluate endometrial safety of three hormone replacement therapy regimens.

METHODS

In a randomized, comparative study in postmenopausal women, endometrial safety was evaluated using (1) no hormone replacement therapy, (2) oral micronized 17 beta-estradiol/oral sequential dydrogesterone, (3) transdermal 17 beta-estradiol/oral sequential dydrogesterone, or (4) oral tibolone. 85 Non-hysterectomised subjects underwent transvaginal ultrasonography immediately before Pipelle biopsy at baseline and subsequently after 12 and 24 months. Endometrial thickness and uterine dimensions were determined by transvaginal ultrasonography, and endometrial thickness (double-layer) was compared with biopsy results.

RESULTS

Endometrial evaluation was conveniently performed by transvaginal ultrasonography, and endometrial thickness correlated well with biopsy findings. If endometrial thickness was < 5 mm, the endometrial biopsy sample was either inactive/atrophic or insufficient for histopathological diagnosis. Hyperplastic or malignant changes were not reported. After 24 months, endometrial thickness was increased both in the oral (P < 0.001) and transdermal (P < 0.001) 17 beta-estradiol/dydrogesterone groups, whereas with tibolone the change in endometrial thickness was not different from controls.

CONCLUSION

transvaginal ultrasonography of the endometrium reliably predicts the histological picture in hormone replacement therapy users. Using 5 mm endometrial thickness as cut-off point, more than 75% of biopsies could be avoided. All three hormone replacement therapies were safe with respect to the endometrium. With sequential 17 beta-estradiol/dydrogesterone the expected progestogen-induced secretory pattern was observed, whereas endometrial histology under tibolone closely mimicked the natural atrophic postmenopausal state.

摘要

目的

比较经阴道超声检查与组织学检查结果,以评估接受激素替代疗法的绝经后妇女的子宫内膜情况,并评估三种激素替代疗法方案的子宫内膜安全性。

方法

在一项针对绝经后妇女的随机对照研究中,采用以下方法评估子宫内膜安全性:(1)不进行激素替代疗法;(2)口服微粉化17β-雌二醇/口服序贯地屈孕酮;(3)经皮17β-雌二醇/口服序贯地屈孕酮;(4)口服替勃龙。85名未行子宫切除术的受试者在基线时进行Pipelle活检前及之后12个月和24个月时接受经阴道超声检查。通过经阴道超声检查确定子宫内膜厚度和子宫大小,并将子宫内膜厚度(双层)与活检结果进行比较。

结果

经阴道超声检查可方便地进行子宫内膜评估,且子宫内膜厚度与活检结果相关性良好。如果子宫内膜厚度<5mm,子宫内膜活检样本要么为静止/萎缩性,要么不足以进行组织病理学诊断。未报告增生或恶性变化。24个月后,口服(P<0.001)和经皮(P<0.001)17β-雌二醇/地屈孕酮组的子宫内膜厚度均增加,而替勃龙组子宫内膜厚度的变化与对照组无差异。

结论

子宫内膜的经阴道超声检查能够可靠地预测激素替代疗法使用者的组织学情况。以5mm子宫内膜厚度作为切点,可避免超过75%的活检。所有三种激素替代疗法在子宫内膜方面都是安全的。使用序贯17β-雌二醇/地屈孕酮时,观察到了预期的孕激素诱导的分泌模式,而替勃龙治疗下的子宫内膜组织学与自然绝经后萎缩状态非常相似。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验